Testing an improved dose of UM171 for cord blood transplant
Part of Blood & lymphatic clinical trials.
This trial tests a higher dose of UM171 to make cord blood transplants safer and more effective for people with certain blood cancers or bone marrow diseases. It aims to help patients who don't have a suitable donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 67 years old.
- You have a high-risk blood cancer or myelodysplasia, or another blood cancer needing a transplant but no suitable donor.
- You have a matched cord blood unit available with enough cells.
- You are healthy enough for transplant, with good heart, lung, liver, kidney function, and a performance score of at least 70%.
- You agree to use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
This trial tests whether adding extra white blood cells (granulocytes) to a cord blood transplant can improve outcomes for people with poor-risk leukemia. It's for patients aged 16 to 55 who have certain genetic mutations or not fully responding to chemotherapy.
This Phase 2 trial studies using a cord blood transplant after finding it is risky enough that standard treatment may not be sufficient. It may help certain children and young adults with specific leukemia, lymphoma, and some non-cancer blood/immune or inherited disorders who do not have a well-matched donor available in time.
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Hear when a new Acute Leukemia, High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.